Loading clinical trials...
Loading clinical trials...
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI ΔM2-2 Lot RSV#002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age
Conditions
Interventions
RSV MEDI ΔM2-2 vaccine
Placebo vaccine
Locations
1
United States
John Hopkins Center for Immunization Research
Baltimore, Maryland, United States
Start Date
August 1, 2011
Primary Completion Date
June 1, 2015
Completion Date
August 1, 2015
Last Updated
December 15, 2015
NCT07220109
NCT07092865
NCT07239583
NCT06534892
NCT04919109
NCT07235397
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions